Canadians prescribed the antipsychotic Rexulti since February 2017 have until August 27 to apply for a share of a $4.75 million settlement. The payout targets those who developed impulse-control disorders, such as binge-eating or gambling, while using the medication.
From $6,500 to $102,000: The Rexulti Payout Scale
The financial compensation available to claimants varies significantly based on the severity of the side effects experienced. According to the report, individuals with mild cases could receive approximately $6,500, while those who suffered more severe impulse-control disorders may be eligible for payments exceeding $102,000.
This tiered structure ensures that the $4.75 million total settlement is distributed proportionally to the level of harm caused. The payout is intended for patients who were prescribed the medication to treat depression or schizophrenia and subsequently developed compulsive behaviors, including compulsive shopping or gambling.
Otsuka and Lundbeck's No-Admission Settlement
The legal resolution involves two primary pharmaceutical entities: Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. As reported, the settlement is a compromise reached between the plaintiffs and the defendants, and it specifically includes no admission of liability by eihter Otsuka Canada Pharmaceutical Inc. or Lundbeck Canada Inc.
This "no-fault" settlement is a common strategic move in pharmaceutical litigation.. It allows the manufacturers to resolve the financial claims of a large group of patients without creating a legal precedent that could be used against them in other jurisdictions or future lawsuits regarding the safety warnings of Rexulti.
The February 2017 Cutoff for Impulse-Control Claims
Eligibility for this class action is strictly defined by a timeline and a set of symptoms. The class covers Canadians who began taking Rexulti on or after February 2017 and subsequently developed impulse-control disorders. This specific date serves as the anchor for the legal claim, likely aligning with when the alleged failure to warn patients and doctors became a central legal issue.
The lawsuit alleged that Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. failed to provide adequate warnings about the potential for the drug to trigger compulsive behaviors . by establishing a clear start date, the court has limited the scope of the settlement to a specific window of prescription and subsequent injury.
Quebec Superior Court's November Approval
The settlement received formal approval from the Quebec Superior Court in November, following a year after the court authorized the national class action. this legal trajectory highlights a growing trend in Canada where class-action lawsuits are used to hold pharmaceutical companies accountable for the transparency of their side-effect disclosures.
The use of a national class action, sanctioned by a provincial court, underscores the systemic nature of the alleged failure to warn. it reflects a broader legal environment where patients are increasingly successful in grouping their claims to challenge the practices of global pharmaceutical firms like Lundbeck and Otsuka.
How many Canadians actually qualify for the $4.75 million pool?
Despite the clarity on the deadline and the payout amounts,several critical details remain unverified in the available reporting. It is currently unknown how many Canadians are expected to file claims, which will ultimately determine if the $4.75 million pool will be exhausted or if individual payouts will be adjusted.
Furthermore, the report does not specify the exact medical documentation required to prove the "severity" of a case to qualify for the $102,000 bracket. Whether a psychiatrist's diagnosis is mandatory or if patient testimony suffices remains an open question for those rushing to meet the August 27 deadline.
Comments 0